Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.
Q2. Of the multiple myeloma patients over the past 6 months, how many were treated with the following:
- Belantamab Mafodotin [Blenrep]
- Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone
- Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone
- Bortezomib [Velcade] ± Dexamethasone
- Bortezomib [Velcade] + Melphalan + Prednisolone/Dexamethasone (VMp or VCd)
- Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD)
- Carfilzomib [Kyprolis] + Dexamethasone
- Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd)
- Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd)
- Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd)
- Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd)
- Daratumumab [Darzalex] monotherapy
- Elranatamab
- Idecabtagene vicleucel [Abecma]
- Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd)
- Isatuximab [Sarclisa] + Pomalidomide [Imnovid] + Dexamethasone (IsaPd)
- Ixazomib [Ninlaro] + Lenalidomide [Revlimid] + Dexamethasone (IRd)
- Lenalidomide [Revlimid] + Dexamethasone
- Lenalidomide [Revlimid] monotherapy
- Panobinostat + Bortezomib + Dexamethasone
- Pomalidomide [Imnovid] + Dexamethasone
- Selinexor + Bortezomib [Velcade] + Dexamethasone
- Selinexor + Dexamethasone
- Talquetamab
- Teclistamab [Tecvayli]
- Any other systemic anti-cancer therapy [please specify]
Q3. In the last 6 months, how many patients have been initiated* on the following regimens?
- Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD)
- Carfilzomib [Kyprolis] + Dexamethasone
- Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd)
- Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd)
- Daratumumab [Darzalex] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Dara-VRd)
- Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd)
- Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd)
- Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd)
- Lenalidomide [Revlimid] monotherapy
- Lenalidomide [Revlimid] + Dexamethasone
- Selinexor + Bortezomib [Velcade] + Dexamethasone
- Selinexor + Dexamethasone
- Any other systemic anti-cancer therapy [please specify]
*Patients are considered initiated if they have not received any of the drugs in the named regimen (either alone or in combination) during the calendar year 2025 prior to initiation.
Q4. In the last 6 months, how many patients have received the following second-line treatment?
- Lenalidomide [Revlimid] + Dexamethasone
